Previous business/academic article Next business/academic article
Business Articles Awards > Asian Antitrust

Ramping Up of Antitrust Enforcement in the Chinese Pharmaceutical Sector

Nicholas French, Freshfields, September 2016

See Ninette Dodoo's resume See Nicholas French's resume See Joy Wong's resume See Kailun Ji's resume

Click here to read the full article online

NDRC fines three Chinese pharmaceutical companies for anti-competitive conduct.
China’s National Development and Reform Commission (NDRC), one of China’s three agencies responsible for antitrust enforcement, recently published its decisions to fine three Chinese companies active in the manufacture of estazolam (a drug commonly used to treat insomnia) for refusing to supply estazolam active pharmaceutical ingredients (APIs) to other estazolam tablet manufacturers and raising estazolam tablet prices. The conduct was held to have infringed China’s Anti-Monopoly Law (AML) which prohibits, among other things, price-fixing and joint-boycotts. The NDRC imposed total fines of approximately RMB 2.6 million (approximately USD 418,057) on the three companies.

Download our brochure